Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03998553
Other study ID # 1901-VLC-006-EB
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 15, 2019
Est. completion date December 17, 2019

Study information

Verified date January 2020
Source Instituto Valenciano de Infertilidad, IVI VALENCIA
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In vitro maturation (IVM) is a technique for obtaining potentially fertilizable oocytes from immature oocytes. An oocyte must be mature both nuclearly and cytoplasmically in order to be competent in the reproductive process. Nuclear maturation involves an oocyte in metaphase II stage and is easily evaluated for its morphology. However, cytoplasmic maturation can only be evaluated by in vitro fertilization of that oocyte A mature nuclear and cytoplasmic oocyte is one capable of producing a viable embryo. This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.

The aim of this study is to evaluate the response to the strategy stimulation with highly purified human menopausal gonadotropin (hMG-HP) administered for three days, in association with a standard methodology of in vitro oocyte maturation (IVM), to be performed on oocyte donors.

The correct functioning of this IVM technique would mean a reduction in the costs of ovarian stimulation treatments, as lower doses and shorter stimulation times are required, which implies lower risks for women derived from the medication and less stress for them.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 17, 2019
Est. primary completion date December 17, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria:

- Woman aged 18-35 years who have belonged to the egg donation program.

- Donors who agree to participate in the pre-trial report and sign informed consent.

- Good previous documented response to ovarian stimulation (at least 10 oocytes total and/or 8 MII).

- Donors with at least one previous cycle of donation, in which all the oocytes obtained were fertilized in fresh

- Patients who come to their last cycle of donation allowed by law

- No personal or family medical disorders history.

- Body mass index between 18-28 kg/m2

- Normal uterus and ovaries, without organic pathology

- Non-polycystic-looking ovaries

- Antral follicle Count (AFC) > 12 from both ovaries on day 2-3 of the menstrual cycle.

- Normal Karyotype

- Negative values of infectious diseases (hepatitis B virus, hepatitis C virus, human immunodeficiency virus and syphilis)

- Analytical with CBC, hemostasis and biochemistry with parameters within normality

Exclusion Criteria:

- Any systemic or metabolic disorder that counterindicates the use of gonadotrophins.

- Any medical condition involving non-inclusion in the oocyte donation program

- Who are taking hormonal contraceptives in the last 3 months

- Severe male Factor (Semen < 3 million)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
IN VITRO MATURATION AND OOCYTE ACTIVATION
This study aims to fine-tune the in vitro maturation (IVM) technique to achieve nuclear mature oocytes, i.e., to mature the oocytes up to the metaphase II stage. In addition, an artificial oocyte activation (AOA) will be carried out to check the cytoplasmic maturation of the oocytes, avoiding the generation of potentially viable embryos.

Locations

Country Name City State
Spain Ivi Valencia Valencia

Sponsors (1)

Lead Sponsor Collaborator
Instituto Valenciano de Infertilidad, IVI VALENCIA

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary rate of obtaining potentially competent oocytes Number of potentially competent oocytes (after in vitro maturation and oocyte activation). 6 months
Secondary Oocyte retrieval rate Number of Oocyte retrieved per punctured follicle. 6 months
Secondary Artificial oocyte activation rate. Number of activated oocyte obtained. 6 months
Secondary In vitro nuclear maturation rate. Number of oocyted with matured nucleous. 6 months
Secondary Fertilization rate Number of Fertilized oocytes obtained in a previous cycle of fresh donation of donor versus the obtained on in vitro maturation cycle. 6 months
Secondary Mature oocytes rate Number of Mature oocytes obtained in of a previous cycle of fresh donation of donor versus the obtained on in vitro maturation cycle. 6 months
See also
  Status Clinical Trial Phase
Completed NCT06239051 - Greening the Humanitas Fertility Center: How to Build a More Sustainable Medical Daily Routine
Recruiting NCT05179993 - Detection of Microplastics in Human Granulosa Cells and in the Follicular Fluid of Women Undergoing ICSI Treatment
Recruiting NCT03767569 - Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Phase 3
Completed NCT03737253 - Hormone Evaluation in Artificial Reproductive Technology Phase 4
Not yet recruiting NCT02237781 - Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins Phase 2/Phase 3
Not yet recruiting NCT02237755 - Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. Phase 2/Phase 3
Completed NCT01477073 - Multiple Dose FSH-GEX(TM) in Healthy Volunteers Phase 1
Recruiting NCT00119925 - 'SPRING'-Study: "Subfertility Guidelines: Patient Related Implementation in the Netherlands Among Gynaecologists" N/A
Recruiting NCT06098495 - Looking for a Blood Epigenetic Signature to Predict Female Infertility
Completed NCT05189145 - Hormonal Monitoring and Progesterone Adjustment in Frozen Embryo Transfer Cycles N/A
Recruiting NCT05050747 - Study to Assess the Effect of Intrauterine Adminstration of HCG Versus Endometrial Injury by Pipelle
Completed NCT01620346 - Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age N/A
Completed NCT00315029 - Patient-Centered Implementation Trial for Single Embryo Transfer N/A
Recruiting NCT03080584 - Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients N/A
Not yet recruiting NCT05106712 - Vitamin D Supplementation and Improvement of PCOS Therapy and IVF Outcomes in Infertile Saudi Women N/A
Recruiting NCT06041204 - Best Treatment for Women With Both (Polycystic Ovary Syndrome) PCOS and Subclinical Hypothyroidism N/A
Completed NCT01604044 - Highly Purified Menotropin (HP-hMG) Versus Recombinant FSH (rFSH) Plus Recombinant LH (rLH) in Intrauterine Insemination Cycles in Women ≥35 Years: a Prospective Randomized Trial. Phase 1
Completed NCT02328924 - There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols? Phase 4
Completed NCT04019899 - Myo-inositol and Vitamin D3 During IVF N/A
Completed NCT02454829 - Follow-up of Ovarian Function in Young Women Who Underwent Ovarian Cortex Cryopreservation N/A